While many people will likely respond positively to the medication, data suggests that tirzepatide and semaglutide are superior drugs for most patients
Longer diabetes duration correlated with older age, a higher proportion of females, a history of stroke, peripheral arterial disease, insulin use, and poorer kidney function
Semaglutide has proven to be a life-changing medication for many people
This article examines semaglutide's pharmacokinetics, elimination timeline, and practical implications for patients and healthcare providers
Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist that has been approved by the US Food and Drug Administration (FDA) for the treatment of obesity and type 2 diabetes
At this stage, patients commonly experience reduced snacking, improved portion control, and longer periods of fullness after meals